Guardant360 CDx

Getting Answers
Blood First
Evidence & Insights

Evidence & Insights

Featured publications, case studies and expert articles

Overview Publications Case Studies Expert Insights
Practice Resources

Practice Resources

Quick and easy access to Guardant360 CDx resources and support.

Overview Peer Education Program
Guardant Portal

How do you treat at the speed of cancer?

The answers are in our blood

Guardant360^® CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors

Highlights

Article

Precise and Rapid Advanced Cancer Treatment Selection

Webinar

Optimizing Advanced Cancer Treatment Using Complete Genomic Profiling

Guardant360 CDx gene list

Inform treatment decisions across all solid tumors

Get essential answers before initiating treatment.

Learn how liquid biopsy has changed the treatment paradigm.

Dr. Nicolas Rohs |
Thoracic Medical Oncologist Mount Sinai Medical Center

Guardant360 CDx is:

First FDA-approved comprehensive liquid biopsy

Complete genomic results in 7 days

Medicare-covered for all solid tumors, regardless of tissue availability

Seamlessly integrate Guardant360 CDx into your practice.

Comprehensive support and educational resources for you and your patients.

Featured Publications

View Evidence & Insights

Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer

Clinical Cancer Research

Clinical Implications of Plasma-Based Genotyping with the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Tepotinib in Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

New England Journal of Medicine

Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

Clinical Lung Cancer

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

Journal of Clinical Oncology

Key Findings

In the NSCLC cohort, 32.2% (19 patients) had a confirmed objective response (complete or partial response) and 88.1% (52 patients) had disease control (objective response or stable disease).
The median progression-free survival was 6.3 months.

Key Findings²⁴

Concordance between Guardant360 and tissue testing was greater than 90% for the four biomarkers with FDA-approved therapies
Guideline-recommended biomarker testing was completed for 95% of patients with Guardant360 vs. 31% with standard-of-care tissue testing
Turnaround time was ~1 week faster with Guardant360 vs. SOC tissue testing

Key Findings²⁵

44% of eligible patients were unable to get complete genomic results from tissue biopsy
2x as many patients had targetable alterations detected by Guardant360 and tissue testing (n=82) versus tissue testing alone (n=47)
86% of patients had a response or stable disease based on RECIST criteria

Key Findings¹⁹

Guardant360 detects guideline-complete alterations in advanced NSCLC patients, including MET exon 14 skipping alterations
ORR and DCR equivalent in Guardant360 and tissue biopsy groups in the VISION trial MET exon 14 skipping NSCLC cohort

Key Findings²⁶

The demands on tissue specimens from diagnostic stains and PD-L1 testing may leave little remaining for genomic profiling
Gaps in genomic biomarker testing can be overcome with new technologies

Key Findings²⁷

Comprehensive ctDNA testing can effectively guide therapy selection
Response rates to therapy selected based on Guardant360 results were consistent with those in tissue-based targeted therapy studies